

# CITATION REPORT

List of articles citing

A comparative pharmacokinetic study of DRL\_BZ, a candidate biosimilar of bevacizumab, with Avastin (EU and US) in healthy male subjects

DOI: 10.1111/bcp.13691

British Journal of Clinical Pharmacology, 2018, 84, 2352-2364.

**Source:** <https://exaly.com/paper-pdf/71191684/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin (EU and US) in healthy male subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2352-2364	3.8	12
12	High-Throughput Bioanalysis of Bevacizumab in Human Plasma Based on Enzyme-Linked Aptamer Assay Using Anti-Idiotypic DNA Aptamer. <i>Analytical Chemistry</i> , <b>2019</b> , 91, 3125-3130	7.8	12
11	Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?. <i>BioDrugs</i> , <b>2019</b> , 33, 437-446	7.9	8
10	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. <i>BioDrugs</i> , <b>2019</b> , 33, 173-181	7.9	12
9	A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 555-562	3.5	9
8	A randomized, double-blind, parallel-group, single-dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 193-202	2.5	1
7	A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 465-474	3.5	0
6	Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-10	5.4	2
5	A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248222	3.7	1
4	A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-9	5.4	0
3	Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2022</b> , 1	2.7	
2	A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. 1-9		
1	Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma. <b>2023</b> , 387-402		0